

COVID-19 Press Briefing

March 19, 2021








The Vaccination Progress Report

7-day average daily doses administered by week as of 3/18/2021*



*7-day average from March 3 – March 9 was 2.2M



Daily Change in COVID-19 Cases, US

January 22, 2020 – March 17, 2021

TOTAL Cases Reported Since 1/22/20

29,349,852

NEW Cases Reported to CDC on 3/17/21

56,900

Change in 7-Day Case Average


-3.0%


Current 7-Day Case Average (3/11/21 - 3/17/21)

53,200

Prior 7-Day Case Average (3/4/21 - 3/10/21)

54,825





*7-day averages exclude historical cases reported retroactively by states





New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – March 16, 2021

Patients Currently Hospitalized with COVID on 3/16/21

33,466

New Admissions on 3/16/21

4,927

Peak in New Admissions (1/5/21)

18,009

Change in 7-Day Average of New Admissions


-4.2%

Current 7-Day Average of New Admissions (3/10/21 - 3/16/21)

4,696

Prior 7-Day Average of New Admissions (3/3/21 - 3/9/21)

4,902







Daily Change in COVID-19 Deaths, United States

January 22, 2020 – March 17, 2021

TOTAL Deaths Reported Since 1/22/2020

535,217

NEW Deaths Reported to CDC on 3/17/21

1,118

Change in 7-Day Death Average

-30.6%

Current 7-Day Death Average (3/11/21 - 3/17/21)


1,025

Prior 7-Day Death Average (3/4/21 - 3/10/21)

1,476

Forecasted Total Deaths by 4/10/21

554,000 to 574,000












WEAR A MASK



STAY 6 FEET APART



AVOID CROWDS



AVOID TRAVEL





B.1.1.7 Variant

- First detected in the U.K. in December 2020
- Reported in at least 94 countries
- First U.S. case of B.1.1.7 variant detected in Colorado on December 29, 2020
- Since then, B.1.1.7 has been detected in 50 jurisdictions in United States and likely accounts for 25-30% of U.S. SARS-CoV-2 infections



Characteristics of B.1.1.7

Of Concern:


- ~50% increased transmission
- Likely increased severity

Encouraging:

- Minimal impact on viral neutralization by EUA monoclonal antibodies
- Minimal impact on viral neutralization by convalescent and post-vaccination sera



Daily Confirmed COVID-19 Cases in Selected European Countries: Potential Effect of B.1.1.7 Variant





Increased Risk of Death with B.1.1.7 Variant



March 10, 2021

Risk of Mortality in Patients Infected With SARS-CoV-2 Variant of Concern 202012/1: Matched Cohort Study

R Challen, L Danon et al.

- 54,906 matched pairs of participants in U.K. one person in pair infected with B.1.1.7 variant; the others with a previously circulating variant
- 64% increased risk of death (32%–104%) with B.1.1.7 variant



International weekly journal of science

March 15, 2021

nature

Increased Mortality in Community-Tested Cases of SARS-CoV-2 Lineage B.1.1.7

NG Davies, RH Keogh et al.

- Analyses of 4,945 COVID-19 deaths where presence or absence of B.1.1.7 known
- Estimated 61% (42–82%) higher risk of death associated with B.1.1.7



Characteristics of B.1.1.7

Of Concern:


- ~50% increased transmission
- Likely increased severity

Encouraging:

- Minimal impact on viral neutralization by EUA monoclonal antibodies
- Minimal impact on viral neutralization by convalescent and post-vaccination sera



Effect of Robust COVID-19 Vaccination Effort in Israel, Where B.1.1.7 Predominates







THE WHITE HOUSE WASHINGTON

WH.GOV